Tegoprubart, an investigational anti-CD40 ligand (CD40L) antibody, was associated with greater improvements in health-related quality of life (HRQoL) and fewer medication-related symptoms than tacrolimus in adults receiving their first kidney transplant, according to patient-reported outcome (PRO) data from the phase 2 BESTOW trial.1 The findings were presented at ASN Kidney Week 2026 in Denver, Colorado.2

“Treatment today with tacrolimus helps prevent organ rejection but at a high cost to patients, with side effects such as kidney toxicity, hypertension, diabetes, tremors, and brain fog. Tegoprubart, which works by targeting the CD40L pathway that is central to how immune cells communicate, has the potential to replace tacrolimus and become the new standard of care immunosuppression therapy across all transplant types, not just kidney transplantation,” corresponding author Andrew Adams, MD, PhD, of the University of Minnesota Medical School, said in a statement.2 “These latest BESTOW trial results are encouraging that we may soon have a new medication that can prevent rejection without the side effects of tacrolimus and transform the broader transplant immunosuppression treatment landscape.”

BESTOW previously showed tegoprubart preserved kidney function vs tacrolimus as the core of the immunosuppressive regimen, with fewer cases of new-onset diabetes and tremor.3 At 18 months, mean eGFR was 74 mL/min/1.73 m² with tegoprubart compared with 61 mL/min/1.73 m² with tacrolimus.4 The present analysis represents the first report of HRQoL outcomes from the trial.1

How Did Tegoprubart Affect Quality of Life in the BESTOW Trial?

BESTOW was a multicenter, randomized, open-label, active-controlled trial. Patients received intravenous tegoprubart 20 mg/kg on days 1, 3, 7, 14, 21, and 28 and every 21 days thereafter, or oral tacrolimus twice daily. Both groups received rabbit antithymocyte globulin induction and maintenance therapy with mycophenolate and corticosteroids.1